A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.
about
Pathway analysis for drug repositioning based on public database miningTamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition of the protein kinase C signaling pathway.Tamoxifen use and acute pancreatitis: A population-based cohort study.CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity.
P2860
A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.
@ast
A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.
@en
type
label
A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.
@ast
A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.
@en
prefLabel
A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.
@ast
A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.
@en
P2093
P1433
P1476
A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer
@en
P2093
B Massidda
L Santuari
P304
P407
P577
2002-07-01T00:00:00Z